177.85
-0.20 (-0.11%)
| Previous Close | 178.05 |
| Open | 179.00 |
| Volume | 90,716 |
| Avg. Volume (3M) | 1,030,062 |
| Market Cap | 8,752,971,776 |
| Price / Earnings (Forward) | 16.69 |
| Price / Sales | 2.30 |
| Price / Book | 2.66 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -0.49% |
| Operating Margin (TTM) | 13.62% |
| Diluted EPS (TTM) | -0.600 |
| Quarterly Revenue Growth (YOY) | -2.70% |
| Quarterly Earnings Growth (YOY) | -62.20% |
| Total Debt/Equity (MRQ) | 92.21% |
| Current Ratio (MRQ) | 1.43 |
| Operating Cash Flow (TTM) | 776.39 M |
| Levered Free Cash Flow (TTM) | 625.62 M |
| Return on Assets (TTM) | 4.26% |
| Return on Equity (TTM) | -0.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Charles River Laboratories Inte | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 1.01% |
| % Held by Institutions | 111.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 210.00 (Barclays, 18.08%) | Buy |
| Median | 196.00 (10.21%) | |
| Low | 165.00 (JP Morgan, -7.23%) | Hold |
| Average | 190.63 (7.19%) | |
| Total | 5 Buy, 3 Hold | |
| Avg. Price @ Call | 171.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 11 Nov 2025 | 185.00 (4.02%) | Hold | 173.50 |
| TD Cowen | 10 Nov 2025 | 197.00 (10.77%) | Buy | 168.97 |
| Baird | 06 Nov 2025 | 199.00 (11.89%) | Buy | 170.88 |
| Barclays | 06 Nov 2025 | 210.00 (18.08%) | Buy | 170.88 |
| 02 Oct 2025 | 195.00 (9.64%) | Buy | 175.36 | |
| JP Morgan | 06 Nov 2025 | 165.00 (-7.23%) | Hold | 170.88 |
| Mizuho | 17 Oct 2025 | 174.00 (-2.16%) | Hold | 178.52 |
| Evercore ISI Group | 03 Oct 2025 | 200.00 (12.45%) | Buy | 177.33 |
| Jefferies | 09 Sep 2025 | 195.00 (9.64%) | Buy | 157.38 |
No data within this time range.
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 28 Nov 1996 | 20 Nov 1996 | 12 Dec 1996 | 0.1 Cash |
| 29 Oct 1996 | 23 Oct 1996 | 12 Dec 1996 | 0.1 Cash |
| 26 Sep 1996 | 19 Sep 1996 | 14 Nov 1996 | 0.1 Cash |
| 28 Aug 1996 | 21 Aug 1996 | 14 Nov 1996 | 0.1 Cash |
| 29 Jul 1996 | 23 Jul 1996 | 14 Nov 1996 | 0.1 Cash |
| 26 Jun 1996 | 20 Jun 1996 | 14 Aug 1996 | 0.1 Cash |
| 29 May 1996 | 20 May 1996 | 14 Aug 1996 | 0.1 Cash |
| 26 Apr 1996 | 18 Apr 1996 | 14 Aug 1996 | 0.1 Cash |
| 27 Mar 1996 | 22 Mar 1996 | 15 May 1996 | 0.1 Cash |
| 27 Dec 1995 | 20 Dec 1995 | 14 Feb 1996 | 0.1 Cash |
| 28 Nov 1995 | 20 Nov 1995 | 14 Feb 1996 | 0.1 Cash |
| 27 Oct 1995 | 17 Oct 1995 | 14 Feb 1996 | 0.1 Cash |
| 27 Sep 1995 | 19 Sep 1995 | 14 Nov 1995 | 0.1 Cash |
| 29 Aug 1995 | 18 Aug 1995 | 14 Nov 1995 | 0.1 Cash |
| 27 Jul 1995 | 18 Jul 1995 | 14 Nov 1995 | 0.1 Cash |
| 28 Jun 1995 | 19 Jun 1995 | 14 Aug 1995 | 0.1 Cash |
| 24 May 1995 | 17 May 1995 | 14 Aug 1995 | 0.1 Cash |
| 24 Apr 1995 | 20 Apr 1995 | 14 Aug 1995 | 0.1 Cash |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |